Stress Urinary Incontinence Clinical Trial
— 1Official title:
Effect of EMG Biofeedback in Female Patients With Stress Urinary Incontinence
NCT number | NCT05366426 |
Other study ID # | 5 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | August 19, 2022 |
Est. completion date | January 15, 2024 |
The aim of this randomized controlled study was to compare the EMG biofeedback method with pelvic floor muscle (PTC) exercises and Sham EMG biofeedback group in women with stress urinary incontinence (SUI) on pelvic floor muscle strength, trunk endurance, subjective perception of improvement, severity of complaints, pad test and quality of life. to determine its effectiveness.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | January 15, 2024 |
Est. primary completion date | December 1, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 30 Years to 65 Years |
Eligibility | Inclusion Criteria: 1.30-65 years old women clinical diagnoses of Urinary Incontinence 2. Clinical diagnoses of Stress Urinary Incontinence (SUI) or Mixt Urinary Incontinence (MUI) with a dominant Stress Urinary Incontinence component 3.Must be have not received treatment with any physical therapy modality in the last 3 months 4.Must be urinary incontinence severity of at least 5 points on Visual Analog Scale 5.Must be able to signed the informed consent form Exclusion Criteria: 1. Severe systemic disease that prevents exercise (Cardiovascular disease, COPD, CVO and/or cancer) 2. Pure urge or MUI with a dominant urge component 3. Plan to change or change medical treatment within the last 3 months due to UUI 4. Visual, auditory, or cognitive deficits that are not suitable for treatment requirements 5. High-intensity sports activities for at least half an hour, at least 2 times a week |
Country | Name | City | State |
---|---|---|---|
Turkey | Ahi Evran University | Kirsehir | City Centre |
Lead Sponsor | Collaborator |
---|---|
Kirsehir Ahi Evran Universitesi |
Turkey,
Terlikowski R, Dobrzycka B, Kinalski M, Kuryliszyn-Moskal A, Terlikowski SJ. Transvaginal electrical stimulation with surface-EMG biofeedback in managing stress urinary incontinence in women of premenopausal age: a double-blind, placebo-controlled, randomized clinical trial. Int Urogynecol J. 2013 Oct;24(10):1631-8. doi: 10.1007/s00192-013-2071-5. Epub 2013 Feb 27. — View Citation
Wu X, Zheng X, Yi X, Lai P, Lan Y. Electromyographic Biofeedback for Stress Urinary Incontinence or Pelvic Floor Dysfunction in Women: A Systematic Review and Meta-Analysis. Adv Ther. 2021 Aug;38(8):4163-4177. doi: 10.1007/s12325-021-01831-6. Epub 2021 Jun 27. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | International Incontinence Inquiry Form ICIQ-SF | International Incontinence Inquiry Form ICIQ-SF Avery et al. and it was reported that the sensitivity, reliability and validity of the scale were high (1). The scale is available in four dimensions. In the first dimension, the frequency of urinary incontinence, the amount of urinary incontinence in the second dimension, the effect of urinary incontinence on daily life in the third dimension, and the conditions that cause urinary incontinence in the fourth dimension are questioned. It was validated in Turkish in 2004 and started to be used in our country. | 0 (baseline) | |
Primary | International Incontinence Inquiry Form ICIQ-SF | International Incontinence Inquiry Form ICIQ-SF Avery et al. and it was reported that the sensitivity, reliability and validity of the scale were high (1). The scale is available in four dimensions. In the first dimension, the frequency of urinary incontinence, the amount of urinary incontinence in the second dimension, the effect of urinary incontinence on daily life in the third dimension, and the conditions that cause urinary incontinence in the fourth dimension are questioned. It was validated in Turkish in 2004 and started to be used in our country. | 8th week (after treatment) | |
Primary | International Incontinence Inquiry Form ICIQ-SF | International Incontinence Inquiry Form ICIQ-SF Avery et al. and it was reported that the sensitivity, reliability and validity of the scale were high (1). The scale is available in four dimensions. In the first dimension, the frequency of urinary incontinence, the amount of urinary incontinence in the second dimension, the effect of urinary incontinence on daily life in the third dimension, and the conditions that cause urinary incontinence in the fourth dimension are questioned. It was validated in Turkish in 2004 and started to be used in our country. | 20th week (3 months after treatment) | |
Primary | Pad test; | Pad test; It is one of the objective tests showing the presence and degree of UI. In the one-hour pad test standardized by ICS, the patient is asked to use a pad of known weight for one hour following 500 mL of non-sodium oral hydration for 15 minutes without urinating. During this period, 30 patients walking, going up and down stairs, sitting up 10 times, coughing 10 times, running for 1 minute, bending down 5 times and washing hands for 1 minute. The weight difference measured on the pad at the end of 1 hour is considered to indicate the amount of urine that has escaped. This amount; If it is less than 1 gram, it is definitely dry, if it is between 2-10 grams, it is considered as mild moderate urinary incontinence, between 10-50 grams as severe urinary incontinence, and over 50 grams as very severe urinary incontinence. To increase the reliability of the test, the duration of the test can be extended from 2 hours to 48 hours. | 0 (baseline) | |
Primary | Pad test; | Pad test; It is one of the objective tests showing the presence and degree of UI. In the one-hour pad test standardized by ICS, the patient is asked to use a pad of known weight for one hour following 500 mL of non-sodium oral hydration for 15 minutes without urinating. During this period, 30 patients walking, going up and down stairs, sitting up 10 times, coughing 10 times, running for 1 minute, bending down 5 times and washing hands for 1 minute. The weight difference measured on the pad at the end of 1 hour is considered to indicate the amount of urine that has escaped. This amount; If it is less than 1 gram, it is definitely dry, if it is between 2-10 grams, it is considered as mild moderate urinary incontinence, between 10-50 grams as severe urinary incontinence, and over 50 grams as very severe urinary incontinence. To increase the reliability of the test, the duration of the test can be extended from 2 hours to 48 hours. | 8th week (after treatment) | |
Primary | Pad test; | Pad test; It is one of the objective tests showing the presence and degree of UI. In the one-hour pad test standardized by ICS, the patient is asked to use a pad of known weight for one hour following 500 mL of non-sodium oral hydration for 15 minutes without urinating. During this period, 30 patients walking, going up and down stairs, sitting up 10 times, coughing 10 times, running for 1 minute, bending down 5 times and washing hands for 1 minute. The weight difference measured on the pad at the end of 1 hour is considered to indicate the amount of urine that has escaped. This amount; If it is less than 1 gram, it is definitely dry, if it is between 2-10 grams, it is considered as mild moderate urinary incontinence, between 10-50 grams as severe urinary incontinence, and over 50 grams as very severe urinary incontinence. To increase the reliability of the test, the duration of the test can be extended from 2 hours to 48 hours. | 20th week (3 months after treatment) | |
Primary | The King's Health Questionnaire | The King's Health Questionnaire (KSA) is a two-part questionnaire that includes 32 items and is frequently used to evaluate the quality of life of patients with incontinence. In addition to two single-item questions such as general health status and impact on quality of life, it includes 7 sub-headings consisting of multiple items. These include: role limitations, physical limitations, social limitations, limitations in personal relationships, emotional problems, sleep and energy disturbances associated with incontinence, and severity measures for incontinence. The second part is the 11-item Symptom Severity Scale, which assesses the presence and severity of urinary symptoms. The score of the Symptom Severity Scale ranges from 0 (best) to 30 (worst). Scores for other KSA domains range from 0 (best) to -100 (worst). Turkish validity and reliability was established (3). | 0 (baseline) | |
Primary | The King's Health Questionnaire | The King's Health Questionnaire (KSA) is a two-part questionnaire that includes 32 items and is frequently used to evaluate the quality of life of patients with incontinence. In addition to two single-item questions such as general health status and impact on quality of life, it includes 7 sub-headings consisting of multiple items. These include: role limitations, physical limitations, social limitations, limitations in personal relationships, emotional problems, sleep and energy disturbances associated with incontinence, and severity measures for incontinence. The second part is the 11-item Symptom Severity Scale, which assesses the presence and severity of urinary symptoms. The score of the Symptom Severity Scale ranges from 0 (best) to 30 (worst). Scores for other KSA domains range from 0 (best) to -100 (worst). Turkish validity and reliability was established (3). | 8th week (after treatment) | |
Primary | The King's Health Questionnaire | The King's Health Questionnaire (KSA) is a two-part questionnaire that includes 32 items and is frequently used to evaluate the quality of life of patients with incontinence. In addition to two single-item questions such as general health status and impact on quality of life, it includes 7 sub-headings consisting of multiple items. These include: role limitations, physical limitations, social limitations, limitations in personal relationships, emotional problems, sleep and energy disturbances associated with incontinence, and severity measures for incontinence. The second part is the 11-item Symptom Severity Scale, which assesses the presence and severity of urinary symptoms. The score of the Symptom Severity Scale ranges from 0 (best) to 30 (worst). Scores for other KSA domains range from 0 (best) to -100 (worst). Turkish validity and reliability was established (3). | 20th week (3 months after treatment) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04829357 -
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
|
||
Completed |
NCT05493735 -
Lidocaine for Pessary Check Pain Reduction
|
Phase 3 | |
Completed |
NCT04512053 -
A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence
|
Phase 2 | |
Active, not recruiting |
NCT06224335 -
Measurement of Intravaginal and Intra-abdominal Pressure and Pad Test During Sports Activities (SPORTVAGPRES)
|
||
Recruiting |
NCT05304312 -
The Role of Kegel Exercises Book to Improve Treatment in Stress Urinary Incontinence Women
|
N/A | |
Not yet recruiting |
NCT05527665 -
Sexual Fonction and Discomfort in Women After Midurethral Sling Surgery, Using PPSSQ
|
||
Not yet recruiting |
NCT04558762 -
Ten Years Follow-up After Insertion of a MUS (Mid Urethral Sling) Due to Stress Urinary Incontinence
|
||
Withdrawn |
NCT02524366 -
A Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement
|
N/A | |
Completed |
NCT01924728 -
Efficacy of Magnetic Stimulation for Stress Urinary Incontinence
|
N/A | |
Completed |
NCT01676662 -
Solace European Confirmatory Trial
|
N/A | |
Unknown status |
NCT01455779 -
Lyrette: Renewing Continence Objective and Subjective Efficacy Study
|
N/A | |
Terminated |
NCT01029106 -
Gynecare TVT Secur for the Management of Stress Urinary Incontinence (SUI)
|
N/A | |
Withdrawn |
NCT00573703 -
Laparoscopic Burch Colposuspension Versus Transobturatory Tape for the Treatment of Female Urinary Stress Incontinence
|
Phase 4 | |
Completed |
NCT01123096 -
Is the Cough Stress Test Equivalent to the 24 Hour Pad Test in the Assessment of Stress Incontinence?
|
N/A | |
Completed |
NCT01770691 -
Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence
|
N/A | |
Completed |
NCT00234754 -
Trans-Obturator Tape Versus Trans-Vaginal Tape for Stress Urinary Incontinence in Women
|
N/A | |
Completed |
NCT00441454 -
Retropubic vs. Transobturator Tension-free Vaginal Tape
|
N/A | |
Completed |
NCT03985345 -
Prospective Evaluation of the Connected EMY Biofeedback Probe in the Management of Stress Urinary Incontinence.
|
N/A | |
Active, not recruiting |
NCT03671694 -
Laser Vaginal Treatment for SUI
|
N/A | |
Completed |
NCT04097288 -
Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects
|
Phase 1 |